Annotation of rs112445441

Allele T is not associated with increased response to cetuximab in people with Colorectal Neoplasms.

Allele complemented to plus chromosomal strand. For patients with G13D, cetuximab did not appear to provide a clinically relevant benefit.

From Publication

Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2015. Schirripa M et al.
PMID:26371285(opens in new window) DOI:10.1093/annonc/mdv385(opens in new window)

Gene

KRAS

Variant

rs112445441

Phenotype Category

Efficacy

Association Significance

The study reports this association is not significant

PharmGKB ID

1447519253

Score
More info on scoring

-0.25

Evidence for Clinical Annotations

This annotation has been used as evidence for the following clinical annotations.

    Study Parameters

    Study type

    clinical trial, prospective

    Study size

    12

    Population description

    Study Cohort: Patients carrying G13D KRAS mutation, progressed after treatment with fluoropyrimidine, oxaliplatin, irinotecan and bevacizumab or with no other valid therapeutic options.

    Note: Alleles in PharmGKB are mapped to the positive chromosomal strand. Therefore, variants in genes on the "minus" strand (eg. VKORC1) are complemented in PharmGKB annotations.

    History

    Loading...